| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Abanoquil targets the α-1 adrenoceptor, a G protein-coupled receptor that mediates the effects of catecholamines (norepinephrine and epinephrine) on smooth muscle contraction. α-1 adrenoceptors are located on vascular smooth muscle cells, where their activation leads to vasoconstriction and increased blood pressure. By blocking these receptors, Abanoquil inhibits the vasoconstrictor effects of catecholamines, leading to relaxation of vascular smooth muscles and a reduction in blood pressure. This mechanism of action makes it a potential antihypertensive agent. Abanoquil's specificity for the α-1 adrenoceptor over other adrenoceptor subtypes contributes to its pharmacological profile.
|
|---|---|
| ln Vitro |
In vitro studies have characterized Abanoquil as a potent α-1 adrenoceptor antagonist. Its activity is typically measured using receptor binding assays and functional assays. In receptor binding assays, Abanoquil competes with radiolabeled ligands for binding to the α-1 adrenoceptor. In functional assays, the compound's ability to inhibit α-1 adrenoceptor-mediated contractions in isolated tissue preparations is measured. For example, isolated rat aorta or other vascular tissues are pre-contracted with an α-1 agonist (e.g., phenylephrine), and the relaxation induced by Abanoquil is measured. These in vitro studies confirm that Abanoquil is a potent and specific α-1 adrenoceptor antagonist.
|
| ln Vivo |
In an erectile response model in monkeys, abanoquil causes constricted tissue strips to shrink [1].
In vivo studies have demonstrated that Abanoquil can relax contracted tissue strips and induce erectile responses in monkey models. This suggests that Abanoquil may have potential in the treatment of erectile dysfunction. The compound's ability to block α-1 adrenoceptors leads to vasodilation, which can increase blood flow to the corpus cavernosum and facilitate erection. Abanoquil has been investigated as a vasodilator and antihypertensive compound. However, specific in vivo protocols and results are not extensively detailed in the available literature. |
| Enzyme Assay |
The in vitro receptor binding assays for Abanoquil measure its affinity for the α-1 adrenoceptor. In a typical assay, membranes are prepared from cells or tissues expressing the α-1 adrenoceptor (e.g., rat cerebral cortex). The membranes are incubated with a radiolabeled ligand that binds to the α-1 adrenoceptor, such as [3H]prazosin. Increasing concentrations of unlabeled Abanoquil are added to compete with the radiolabeled ligand for binding. After incubation, the bound and free ligand are separated by filtration, and the radioactivity is measured. The Ki is determined from the competition curve. These assays provide a quantitative measure of Abanoquil's affinity for the α-1 adrenoceptor.
|
| Cell Assay |
In vitro functional assays for Abanoquil measure its ability to inhibit α-1 adrenoceptor-mediated responses. A common assay is the isolated tissue bath assay. In this assay, isolated rat aorta or other vascular tissues are mounted in a tissue bath and equilibrated under tension. The tissues are contracted with an α-1 agonist, such as phenylephrine, to induce a stable contraction. Abanoquil is then added cumulatively, and the relaxation is recorded. The concentration-response curve is generated, and the IC50 is determined. These functional assays confirm that Abanoquil is an antagonist at the α-1 adrenoceptor.
|
| Animal Protocol |
In vivo animal experiments for Abanoquil have been conducted in monkey models to study its effects on erectile function. In a typical study, Abanoquil is administered to monkeys, and the erectile response is measured. The compound has been shown to relax contracted tissue strips and induce erectile responses. These findings suggest that Abanoquil may have potential in the treatment of erectile dysfunction. Abanoquil has also been investigated as a vasodilator and antihypertensive compound in other animal models.
|
| ADME/Pharmacokinetics |
Abanoquil has a molecular weight of 395.45 g/mol and a molecular formula of C22H25N3O4. It has a predicted density of 1.246 g/cm³. For research use, Abanoquil is typically supplied as a powder. It is soluble in DMSO and other organic solvents. For storage, it is recommended to keep the powder at -20°C in a dry, dark environment. Pharmacokinetic properties such as absorption, distribution, metabolism, and excretion (ADME) have not been extensively characterized. Abanoquil is a research compound and is not intended for human or veterinary use.
|
| Toxicity/Toxicokinetics |
Detailed toxicity data for Abanoquil is not provided in standard product descriptions. As a research compound, its toxicity profile has not been extensively characterized. Abanoquil is an α-1 adrenoceptor antagonist, and its toxicity would be related to its effects on the cardiovascular system. Blockade of α-1 adrenoceptors can lead to hypotension and reflex tachycardia. As with all research chemicals, standard laboratory safety precautions should be followed when handling Abanoquil. Its use is limited to research applications and it is not intended for human or veterinary use.
|
| References |
|
| Additional Infomation |
Abanoquil is a research compound and is not approved for any clinical or therapeutic use. It is a potent and specific α-1 adrenoceptor antagonist and an antiarrhythmic agent. Abanoquil is a pharmacological agent primarily investigated as a vasodilator and antihypertensive compound. By blocking alpha-adrenergic receptors, Abanoquil leads to the relaxation of vascular smooth muscles and a reduction in blood pressure. Abanoquil has also been studied for potential use in erectile dysfunction research. Its mechanism of action involves antagonizing the α-1 adrenoceptor, thereby inhibiting catecholamine-induced vasoconstriction.
|
| Molecular Formula |
C22H25N3O4
|
|---|---|
| Molecular Weight |
395.451605558395
|
| Exact Mass |
395.185
|
| Elemental Analysis |
C, 66.82; H, 6.37; N, 10.63; O, 16.18
|
| CAS # |
90402-40-7
|
| Related CAS # |
118931-00-3 (mesylate);90402-40-7;
|
| PubChem CID |
164089
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.246g/cm3
|
| Boiling Point |
630.3ºC at 760mmHg
|
| Flash Point |
335ºC
|
| LogP |
4.06
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
538
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=C(C=C2CN(CCC2=C1)C3=NC4=CC(=C(C=C4C(=C3)N)OC)OC)OC
|
| InChi Key |
ANZIISNSHPKVRV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H25N3O4/c1-26-18-7-13-5-6-25(12-14(13)8-19(18)27-2)22-10-16(23)15-9-20(28-3)21(29-4)11-17(15)24-22/h7-11H,5-6,12H2,1-4H3,(H2,23,24)
|
| Chemical Name |
2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-6,7-dimethoxyquinolin-4-amine
|
| Synonyms |
Abanoquil; UK 52046; UK-52046; UK52046; 90402-40-7; abanoquilo; F738MWY53L; DTXSID40238163;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~31.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5288 mL | 12.6438 mL | 25.2876 mL | |
| 5 mM | 0.5058 mL | 2.5288 mL | 5.0575 mL | |
| 10 mM | 0.2529 mL | 1.2644 mL | 2.5288 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
